Breast Patents (Class 514/19.4)
-
Publication number: 20130345145Abstract: The present invention concerns a combination of (i) a polypeptide comprising ATIP3 or a biologically active fragment thereof, and (ii) a chemotherapeutic drug that is an antimitotic agent, for simultaneous or sequential use in the treatment of a patient suffering from cancer, e.g. a triple-negative breast cancer. The present invention also relates to a polypeptide comprising ATIP3 or a biologically active fragment thereof, for use in sustaining drug effect, increasing or restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug that is an anti-mitotic agent. The present invention further provides biologically active polypeptides that comprise or consist of fragments of ATIP3, and antibodies binding thereto.Type: ApplicationFiled: March 12, 2012Publication date: December 26, 2013Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)Inventors: Clara Nahmias, Sylvie Rodrigues-Ferreira
-
Patent number: 8614193Abstract: The subject application pertains to a compound of structure IX or X: or a pharmaceutically acceptable salt thereof, wherein: X is —C(?O)N(R10)— or —CH(OPr3) —; R7, R9 and R10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr1 and Pr2 are the same or different and represent hydrogen or a thiol protecting group; Pr3 is hydrogen or an alcohol protecting group; R1, R2, R5 and R6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R1 and R2 and/or R5 and R6, taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R1 and R2 is not hydrogen, or each of R5 and R6 is not hydrogen.Type: GrantFiled: May 22, 2009Date of Patent: December 24, 2013Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Cyrille Davy Tomassi, Alexander Richard Liam Cecil, Thomas James Hill
-
Publication number: 20130331334Abstract: The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.Type: ApplicationFiled: May 2, 2013Publication date: December 12, 2013Applicant: United States Department of Health and Human ServicesInventor: Raj K. Puri
-
Publication number: 20130331335Abstract: Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Applicant: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20130323283Abstract: Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.Type: ApplicationFiled: December 1, 2011Publication date: December 5, 2013Applicants: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Wayne W. Hancock, Steven M. Albelda, Philip A. Cole
-
Publication number: 20130324458Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: David GLASS, Shou-Ih HU
-
Patent number: 8597645Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: October 6, 2011Date of Patent: December 3, 2013Assignee: New York UniversityInventors: Robert Schneider, Sumayah Jamal
-
Publication number: 20130316957Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20130316955Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.Type: ApplicationFiled: January 9, 2012Publication date: November 28, 2013Applicant: MERCK PATENT GMBHInventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Brigitta Leuthner
-
Patent number: 8586543Abstract: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.Type: GrantFiled: August 17, 2009Date of Patent: November 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Ahmed A. Samatar, Brian Long, Priya Dayananth, Diane Levitan, Marsha Smith
-
Publication number: 20130302357Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Patent number: 8580743Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.Type: GrantFiled: August 22, 2012Date of Patent: November 12, 2013Assignee: Galpharma Co., Ltd.Inventors: Nozomu Nishi, Mitsuomi Hirashima, Akira Yamauchi, Aiko Ito
-
Publication number: 20130288984Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof.Type: ApplicationFiled: January 11, 2012Publication date: October 31, 2013Applicant: GLAXOSMITHKLINE LLCInventor: Rakesh Kumar
-
Publication number: 20130274203Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: ApplicationFiled: September 14, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Dhanalakshmi Chinnasamy
-
Patent number: 8557787Abstract: Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P21-Associated NcRNA, DNA damage Activated), inhibits the expression of apoptotic genes normally activated by the transcription factor NF-YA. Inhibitors of PANDA sensitize cancerous cells to chemotherapy and can be used in combination with chemotherapeutic agents for treatment of cancer.Type: GrantFiled: May 11, 2012Date of Patent: October 15, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Howard Y. Chang, David J. Wong, Tiffany Hung
-
Patent number: 8551951Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: January 22, 2010Date of Patent: October 8, 2013Assignee: Aenorasis SA Pharmaceuticals and Medical DevicesInventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20130252905Abstract: Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes.Type: ApplicationFiled: March 10, 2013Publication date: September 26, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Chaya MOROZ
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Patent number: 8530431Abstract: Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.Type: GrantFiled: March 23, 2010Date of Patent: September 10, 2013Assignee: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20130225478Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.Type: ApplicationFiled: July 19, 2011Publication date: August 29, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Avner Fink, Eliran-Moshe Reuven, Liraz Shmuel-Galia
-
Publication number: 20130225503Abstract: Embodiments of the present invention regard TEX14 peptides for cancer treatment. In particular, the TEX14 peptides comprise a GPPX3Y motif. Methods, compositions, and kits are encompassed.Type: ApplicationFiled: September 30, 2010Publication date: August 29, 2013Applicant: Baylor Licnensing GroupInventors: Martin M. Matzuk, Tokuko Iwamori, Michael P. Greenbaum, Lang Ma, Naoki Iwamori
-
Patent number: 8518887Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: June 25, 2010Date of Patent: August 27, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Patent number: 8513199Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.Type: GrantFiled: May 8, 2012Date of Patent: August 20, 2013Assignee: Amgen Inc.Inventors: Kenneth Allan Brasel, James F Smothers, Douglas Pat Cerretti
-
Publication number: 20130209541Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.Type: ApplicationFiled: April 16, 2010Publication date: August 15, 2013Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20130210711Abstract: The invention relates to a compound of the general structure (I), where R is a hydrogen atom (II) or an unsubstituted, monosubstituted or polysubstituted C1-C20-alkyl, wherein the alkyl is straight, branched, cyclic and/or partially unsaturated, or an unsubstituted, monosubstituted or polysubstituted phenyl group.Type: ApplicationFiled: April 30, 2010Publication date: August 15, 2013Applicant: GEOMAR Helmholtz-Zentrum fur Ozeanforschung KielInventors: Johannes Imhoff, Inga Knopf-Kajahn, Gerhard Lang, Jutta Wiese, Arne Peters
-
Patent number: 8507443Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.Type: GrantFiled: August 19, 2005Date of Patent: August 13, 2013Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto
-
Patent number: 8507442Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: GrantFiled: June 20, 2011Date of Patent: August 13, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Publication number: 20130196927Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its cIAP degradation properties.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Inventors: Christopher BENETATOS, Srinivas CHUNDURU, Stephen CONDON, Mark McKINLAY, Yasuhiro MITSUUCHI
-
Publication number: 20130190223Abstract: The compounds of the present invention are non-immunosupressive cyclosporine analogue molecules that are able to bind cyclophilin. Said compounds include a modified side chain of amino acid I of cyclosporin A, consisting of an oxyalkyl having substituents R?, R1 and R2, where R? is H or Acetyl; R1 is a saturated or unsaturated straight chain or branched aliphatic carbon chain; and R2 may be a hydrogen; a unsubstituted, N substituted or NN disubstituted amide; a N substituted or unsubstituted acyl protected amine; a carboxylic acid; a N substituted or unsubstituted amine; a nitrile; a ester; a ketone; a hydroxy, dihydroxy, trihydroxy or polyhydroxy alkyl; or a substituted or unsubstituted aryl.Type: ApplicationFiled: July 3, 2009Publication date: July 25, 2013Applicant: ISOTECHNIKA PHARMA INC.Inventors: Alexander Hegmans, Bruce W. Fenske, David P. Czajkowski, Darren R. Ure, Shin Sugiyama, Dan J. Trepanier, David H. McGlade, Mark D. Abel
-
Publication number: 20130189291Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: ApplicationFiled: January 17, 2013Publication date: July 25, 2013Applicant: Oncotherapy Science, Inc.Inventor: Oncotherapy Science, Inc.
-
Publication number: 20130190250Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.Type: ApplicationFiled: September 14, 2012Publication date: July 25, 2013Inventors: Preeti G. Lal, Jennifer L. Jackson, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Susan K. Sather, Purvi Shah
-
Publication number: 20130189256Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: July 25, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Patent number: 8492345Abstract: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.Type: GrantFiled: November 14, 2011Date of Patent: July 23, 2013Assignee: Northwestern UniversityInventors: Richard B. Silverman, Shouxin Liu, Wenxin Gu, Thomas E. Adrian, Gerald A. Soff
-
Publication number: 20130184223Abstract: Disclosed are compositions and methods related to new targets for cancer treatment the modulation of autophagy.Type: ApplicationFiled: May 20, 2011Publication date: July 18, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Hartmut Land, Conan Kinsey
-
Publication number: 20130184201Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicants: Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Patent number: 8481498Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: February 10, 2012Date of Patent: July 9, 2013Inventor: Steven Hoffman
-
Patent number: 8481497Abstract: [PROBLEMS] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.Type: GrantFiled: May 29, 2008Date of Patent: July 9, 2013Assignees: Sapporo Medical University, The University of TokyoInventors: Kohzoh Imai, Shigeru Sasaki, Tsutomu Seito
-
Publication number: 20130164218Abstract: This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Publication number: 20130165381Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: ApplicationFiled: January 16, 2013Publication date: June 27, 2013Applicant: SILENCE THERAPEUTICS AGInventor: SILENCE THERAPEUTICS AG
-
Patent number: 8470969Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.Type: GrantFiled: June 23, 2010Date of Patent: June 25, 2013Assignee: Genentech, Inc.Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh, Evan E. Shave, Patricia A. Rancatore
-
Publication number: 20130149306Abstract: The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody.Type: ApplicationFiled: May 6, 2011Publication date: June 13, 2013Applicants: NETRIS PHARMA, CENTRE NATIONAL DE LA DECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Amélie Royet, Fanny Mann, Sophie Chauvet, Jonathan Luchino
-
Patent number: 8461117Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.Type: GrantFiled: December 28, 2007Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
-
Patent number: 8460661Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: November 30, 2011Date of Patent: June 11, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
-
Publication number: 20130142797Abstract: The present invention relates to methods of treating virus-induced cancer with the polypeptides that are capable of killing cells. The polypeptide comprises a targeting agent covalently attached to a channel-forming moiety.Type: ApplicationFiled: December 7, 2012Publication date: June 6, 2013Applicant: PHEROMONICIN BIOTECH, LTD.Inventor: PHEROMONICIN BIOTECH, LTD.
-
Publication number: 20130142867Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: ApplicationFiled: October 25, 2011Publication date: June 6, 2013Applicant: Academia SinicaInventors: John Yu, Alice L. Yu, H.C. Wu, I-Ju Chen, Sheng-Hung Wang
-
Publication number: 20130143811Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: ApplicationFiled: May 25, 2011Publication date: June 6, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Patent number: 8454968Abstract: The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo.Type: GrantFiled: August 5, 2009Date of Patent: June 4, 2013Assignee: Toray Industries, Inc.Inventors: Fumiyoshi Okano, Masaki Shimizu, Takanori Saito
-
Publication number: 20130137628Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.Type: ApplicationFiled: May 11, 2011Publication date: May 30, 2013Applicant: ESPERION THERAPEUTICS, INC.Inventors: Roger S. Newton, Rai Ajit K. Srivastava, Timothy R. Hurley, Clay Cramer, Sergey V. Filippov, Stephen L. Pinkosky
-
Patent number: 8450283Abstract: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.Type: GrantFiled: September 10, 2009Date of Patent: May 28, 2013Assignee: National Taiwan UniversityInventors: Pan-Chyr Yang, Tse-Ming Hong, Yuh-Ling Chen, Ang Yuan, Yi-Ying Wu
-
Publication number: 20130129759Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.Type: ApplicationFiled: June 27, 2012Publication date: May 23, 2013Applicant: Oncotherapy Science, Inc.Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida